

Case report

Sarcomatoid Bladder Tumor - A Rare Variant of Transitional Cell Carcinoma

ABSTRACT

Aims: Transitional cell carcinoma (TCC) of the bladder encompasses various tumor variants, with the sarcomatoid subtype being one of the rarest and most aggressive. This case report aims to present the clinical characteristics, diagnosis, surgical intervention, and post-operative management of a non-smoking 71-year-old female patient who presented with gross hematuria and was subsequently diagnosed with a sarcomatoid bladder tumor through a series of diagnostic evaluations. The report intends to contribute to the existing literature on this rare tumor variant and shed light on the diagnostic challenges and meticulous surgical and post-operative management in the absence of chemoradiation therapy.

Study design: This case report presents a single case study of a patient diagnosed with sarcomatoid bladder tumor.

Methodology: The patient was a 71-year-old female with no history of smoking, who presented with gross hematuria. Diagnostic evaluations, including imaging studies and histopathological examinations, were performed to determine the presence of a sarcomatoid bladder tumor. Surgical intervention was conducted to remove the tumor, followed by post-operative management without chemoradiation therapy.

Results: The case report presents the successful diagnosis and management of a sarcomatoid bladder tumor in the described patient. Detailed clinical, histopathological, and imaging findings are provided, showcasing the challenges and treatment decisions in the absence of chemoradiation therapy.

Conclusion: This case report underscores the significance of recognizing and managing rare tumor variants like sarcomatoid bladder tumor. It adds to the existing medical literature on this subject and emphasizes the importance of careful diagnostic evaluation and meticulous surgical and post-operative care to achieve favorable outcomes in patients affected by this aggressive variant. Further studies and case reports are warranted to advance our understanding and optimize the management of sarcomatoid bladder tumors.

Comment [CN1]: Avoid this repetition

Comment [CN2]: Avoid repetition

Keywords: Bladder cancer, transitional cell carcinoma, sarcomatoid variant, radical cystectomy

1. INTRODUCTION

Sarcomatoid carcinoma of the urinary bladder (SCUB) is a rare and aggressive form of bladder cancer comprising less than 1% of all bladder cancers [1]. One of its characteristics is the presence of an epithelial urothelial component with a predominant spindle cell contingent and a sarcomatoid contingent [2]. Despite these tumors being widely associated

with poor prognosis, the literature remains constrained to case reports and no consensus on an optimal treatment and management exists [1]. However, radical cystectomy with extensive lymph node dissection has shown more consistent results as highlighted by a series of five case reports by Kadouri et al. [2]. Patients who refused surgical treatment by radical cystectomy and opted for chemoradiation therapy have shown more varying outcomes. In a case report by Kumar et al., a 74-year-old male smoker with SCUB refused radical cystectomy and opted for Gemcitabine and Cisplatin chemotherapy [3]. The patient died nine months after the diagnosis. No standard treatment for this disease has been established, but the radical surgical option appears to be the mainstay of treatment. On the other hand, there exists cases where opting for chemoradiation rather than radical cystectomy had achieved complete response to chemoradiation such in the case presented by Wallach et al. [4]. In this case, a 67-year-old woman with bladder carcinoma of sarcomatoid differentiation presented with weeks of hematuria and was advised to undergo radical cystectomy as the traditional treatment but opted for a bladder-preserving chemoradiation therapy as a reasonable alternative [4]. The patient was able to achieve complete response and preserve bladder function. Such cases where nonsurgical therapy for bladder tumors is done are scarce especially because these tumors show poor response to primary chemoradiation therapy [4]. Finally, histopathology is difficult but crucial in the identification of the tumor where immunohistochemistry must be utilized to establish a final diagnosis of the tumor [5].

2. CASE PRESENTATION

In this case report, we describe a 71-year-old female patient, with previous medical history only pertinent for asthma and hypertension, and previous surgical history pertinent for hysterectomy, appendectomy and total knee replacement. She initially presented to a peripheral center with gross hematuria. On lab workup, patient was anemic with a decreased TIBC, and elevated RBCs in her urinalysis. Labs were otherwise normal. An initial ultrasound revealed bilateral renal cortical cysts and a possible bladder tumor. CT KUB was done, confirming the presence of a suspicious mass in the bladder (Figure 1), and prompting her to present to our care for further management. Otherwise, the patient is a non-smoker, and only complains of a seasonal allergy.

Comment [CN3]: Plain or contrast

Formatted: Highlight



Figure 1: CT KUB

3. RESULTS AND DISCUSSION

Under our care, a cystoscopy confirmed the presence of a bladder tumor invading the left lateral wall of the bladder. Morphologically, tumor had the features of a transitional cell carcinoma, that bore signs of poor differentiation (figure 2). TURBT (transurethral resection of bladder tumor) was done. A 4.5x4.5x3cm bladder TCC was revealing, and was high-grade (G4/G4), invading the muscularis propria (pT2). The patient was then prepped for radical cystectomy in addition to ileal conduit (Bricker technique). During surgery, the anterior vaginal wall was also resected, and an extended pelvic lymph node dissection revealed the presence of multiple enlarged iliac nodes. Post-operatively, the patient initially suffered from a partial small bowel obstruction, which delayed passage of flatus and was treated via NG tube and GOMCO. Furthermore, urine leak was initially noted through high drain inputs and low urostomy inputs, though was resolved on Day 7 post-op without need for nephrostomies. Finally, the pathology report depicts an 8 x 7 x 4 cm radical cystectomy specimen that shows a high grade invasive urothelial carcinoma (TCC) with sarcomatoid differentiation in 15% of the tumor. All bladder layers and perivascular adipose tissue are invaded, with 5mm tumor involvement in the radial/adipose tissue margin. Additionally, The tumor exhibits lymphovascular permeations and perineural invasion. Both the urethral and ureteral margins are free of neoplasia, and no neoplasia was observed in the examined lymph nodes. There is mild chronic inflammation of the anterior vaginal wall with no evidence of malignancy.

Comment [CN4]: Whether this was seen on CT scan

Formatted: Font: 10 pt, Highlight

Formatted: Highlight

Formatted: Font: 10 pt, Highlight

Comment [CN5]: Full forms

Comment [CN6]: Was any imaging was done to determine the site of leak

Comment [CN7]: Input or output?

Formatted: Font: 10 pt, Highlight

Formatted: Font: 10 pt, Highlight

Comment [CN8]: Input or output?

Formatted: Font: 10 pt, Highlight

Comment [CN9]: Perivascular or peri-vesical

Formatted: Font: 10 pt, Highlight



Figure 2: Cystoscopic image of the bladder during examination

Varying case studies describe multimodality as the ideal treatment for this particular variant of bladder TCC. The common mode of care, however, remains radical cystectomy coupled with extended pelvic lymph node dissection, with or without adjuvant chemotherapy. Indeed, radiotherapy is seldom indicated, due to the known resistance of other types of sarcomas [4]. It therefore seems wisest to start with a surgical approach, followed by adjuvant treatment based on the surgical pathological invasiveness of the disease. That is, a radical cystectomy followed by extensive lymph node dissection. Adjuvant therapy like radiotherapy or chemotherapy is usually given to prevent recurrences [6]. These are mostly indicated in the presence of high grade, margin positivity, lymphnode positivity or extravesical spread [6]. However, prognosis in the aforementioned scenarios is worse, making the survival better for those treated with radical cystectomy.

4. CONCLUSION

Given its aggressive nature and rare variation, SCUB has multiple unsubstantiated guidelines of care, derived mainly from the rarity of the entity in literature. It therefore becomes our responsibility to further study it, and to treat it as seen fit by the many differing patient-related circumstances. Early diagnosis and the utilization of histopathology and immunochemistry allows for better treatment outcomes.

Formatted: Font: 10 pt, Highlight

Comment [CN10]: Why was adjuvant treatment not given in your case?

Formatted: Highlight

Comment [CN11]: Follow up of your case? Months / years post op? Any long term complication or adverse event, including death

CONSENT

As per international standard or university standard, parental(s) written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

REFERENCES

1. Pagliaro L. Primary sarcomas and Other sarcomatoid tumors of the Bladder. In: Rare Genitourinary Tumors. Switzerland: Springer International Publishing AG; 2016:109-120.
2. Kadouri Y, Ouskri S, Sayegh HE, Benslimane L, Nouini Y. Sarcomatoid carcinoma of the urinary bladder: analysis of five cases and literature review. *Pan Afr Med J.* 2020 Aug 29;36:369. doi: 10.11604/pamj.2020.36.369.25036. PMID: 33235646; PMCID: PMC7666685.
3. Kumar Pal A, Srinivas BH, Kalra S, Dorairajan LN, Sreenivasan Kodakkattil S. Sarcomatoid urothelial carcinoma of the urinary bladder with chondrosarcomatous and concurrent divergent squamous cell carcinoma differentiation- A rare entity. *Cureus [Internet].* 2022;14(12):e33107. Available from: <http://dx.doi.org/10.7759/cureus.33107>
4. Wallach JB, Wang B, Sanfilippo N. High-grade hyperinvasive sarcomatoid urothelial bladder carcinoma demonstrating complete response to bladder-preserving chemoradiation. *Curr Oncol.* 2009 May;16(3):55-7. doi: 10.3747/co.v16i3.396. PMID: 19526087; PMCID: PMC2695712.
5. Molina-Cerrillo J, Martínez-Sáez O, Alonso-Gordoa T, et al. Primary Sarcomatoid Tumor of the Bladder: A Different Entity but the Same Approach? *Clinical genitourinary cancer.* 2015;13:493-498.
6. Daga G, Kerkar P. Sarcomatoid Carcinoma of Urinary Bladder: a Case Report. *Indian J Surg Oncol.* 2018 Dec;9(4):644-646. doi: 10.1007/s13193-018-0769-z. Epub 2018 May 16. PMID: 30538409; PMCID: PMC6265164.